Clinical trials: Tamoxifen
Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
The aim of the study is to evaluate whether tamoxifen at a low dose of 5mg/d reduces in the long term the incidence of invasive breast cancer and ductal carcinoma in situ, DCIS (DIN 1c, 2, 3) of the breast, in woman operated for…
- Conditions
- Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm, Breast Neoplasms, Atypical Hyperplasia
- Trial name
- TAM-01 (NCT01357772)
- Testing
- Tamoxifen
- Where
- 14 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Andrea DeCensi
Pre-menopausal Breast Cancer, PI3K Pathway Inhibition
A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
Based on the evidence acquired in the post-menopausal setting with everolimus and on pre-clinical evidences supporting the investigation of PI3K inhibitors, such as alpelisib and buparlisib, in combination with endocrine therapy…
- Trial name
- B-YOND (NCT02058381)
- Testing
- alpelisib (BYL719), buparlisib (BKM120)
- Where
- 15 sites in Hong Kong, South Korea and 2 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Breast Cancer Female
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
This is a one stage phase II study with a single arm design. It will be conducted in HER-2 positive breast cancer patients in Nigeria who are chemotherapy/hormonal treatment naive.
- Conditions
- Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer, Breast Cancer Stage II
- Trial name
- NCT03879577
- Testing
- Docetaxel, Herceptin, FEC
- Where
- Nigeria
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Early Breast Cancer, Metabolic Health
Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy
This clinical trial aims to investigate early metabolic health changes in early breast cancer patients that initiate antihormone therapy.
- Conditions
- Early Breast Cancer, Metabolic Health, Estrogen Receptor Positive Breast Cancer
- Trial name
- EMETA (NCT06623903)
- Where
- Denmark
- Volunteers
- 112 people
- Sponsor
- Aarhus University Hospital
Healthy
DP-R213 Pharmacokinetics Study
A randomized, open-label, crossover, Phase I clinical trial to compare the pharmacokinetics of DP-R213 (Raloxifenel and Cholecaliferol fixed dose combinations) in comparison to each component administered alone in healthy male…
- Trial name
- NCT02762643
- Testing
- DP-R213, Raloxifene, Cholecaliferol
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Alvogen Korea
SARS CoV 2 Infection
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19.
- Trial name
- NCT05172050
- Testing
- Raloxifene
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 61 people
- Sponsor
- Dompé Farmaceutici S.p.A
Breast Cancer
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance.
- Trial name
- NCT00899197
- Testing
- tamoxifen citrate, gene expression analysis, protein expression analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Adjuvant Treatment
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor.
- Conditions
- Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
- Trial name
- SWIVEL (NCT07071038)
- Testing
- Switch, Guideline Directed Intervention (GDI)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer, Breast Carcinoma
Therapeutic Dose Monitoring (TDM) of Tamoxifen
Tamoxifen is a potent and effective drug reducing the risk of dying from breast cancer in the adjuvant setting. Although more modern drugs have partly replaced tamoxifen, it is helpful in the neoadjuvant and metastatic settings…
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Tumors, Cancer of Breast
- Trial name
- NCT05133674
- Testing
- Tamoxifen 20 mg
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital
Breast Cancer
Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376
The investigators hypothesize that the TCF20 rs932376 locus controls endoxifen levels in estrogen receptor (ER)-positive breast cancer patients on tamoxifen therapy and that the requirement of tamoxifen dose to achieve…
- Trial name
- NCT04961632
- Testing
- Tamoxifen
- Where
- Singapore
- Volunteers
- 75 people
- Sponsor
- National Cancer Centre, Singapore
Breast Cancer
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells.
- Trial name
- NCT00003906
- Testing
- Raloxifene, Tamoxifen
- Where
- 516 sites in United States, Canada and 1 more
- Volunteers
- 19,747 people
- Sponsor
- NSABP Foundation Inc
Metastatic Breast Cancer
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to identify the highest tolerable dose of pyrotinib in combination with vinorelbine and to assess the safety and efficacy of the combination in Patients With HER2-Positive Locally Advanced or…
- Trial name
- NCT03997539
- Testing
- Pyrotinib, Treatment of physician's choice, vinorelbine
- Volunteers
- 256 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women
Breast cancer is the most frequently diagnosed cancer in women with the majority receiving an endocrine therapy (ET) in the adjuvant setting.
- Trial name
- NCT02480218
- Testing
- Neuropsychological test battery
- Where
- Canada
- Volunteers
- 47 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer
PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Non-randomized, open label, multicentric translational research study in women with untreated invasive breast carcinoma eligible for primary surgery (Stage I-IIIA).
- Trial name
- PAMELA (NCT01973660)
- Testing
- Lapatinib, Trastuzumab, Endocrine Therapy
- Where
- 22 sites in Spain
- Volunteers
- 151 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer, Osteoporosis
Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02
RATIONALE: Gathering information over time from bone density and laboratory tests of women with breast cancer treated with triptorelin and tamoxifen or exemestane may help the study of breast cancer in the future.
- Trial name
- TEXT-Bone (NCT00963417)
- Testing
- laboratory biomarker analysis, dual x-ray absorptiometry
- Where
- 13 sites in Australia, Belgium and 1 more
- Volunteers
- 119 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002460
- Testing
- goserelin acetate, tamoxifen citrate, ablative endocrine surgery
- Where
- 34 sites in Belgium, United Kingdom
- Sponsor
- Cancer Research UK
Osteoporosis
Back Pain in Patients With Severe Osteoporosis
The purpose of this study is to compare the effectiveness of teriparatide versus therapies that decrease bone loss to prevent new or worsening back pain in patients with osteoporosis seen in clinical practice.
- Trial name
- NCT00761332
- Testing
- teriparatide, antiresorptives
- Where
- 15 sites in Hong Kong, India and 7 more
- Volunteers
- 650 people
- Sponsor
- Eli Lilly and Company
Invasive Early Breast Cancer
A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
The IES study (A5991012) investigated 4742 patients treated for 2 to 3 years with tamoxifen, who either continued the same treatment or switched to Aromasin® for a total treatment period of 5 years.
- Trial name
- NCT01121549
- Testing
- Aromasin
- Where
- 40 sites in Romania
- Volunteers
- 378 people
- Sponsor
- Pfizer
Breast Adenocarcinoma, HER2 Positive Breast Carcinoma
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer that is…
- Conditions
- Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT00005970
- Testing
- Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 157 sites in United States, Canada and 2 more
- Volunteers
- 3,436 people
- Sponsor
- National Cancer Institute (NCI)
Osteoporosis
Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis
Increased bone formation in the absence of accelerated resorption is resulting in a marked anabolic response to teriparatide (TPTD) during the early phase after treatment initiation.
- Trial name
- Confors (NCT01535027)
- Testing
- teriparatide, teriparatide and raloxifene, teriparatide and alendronate
- Where
- Austria
- Volunteers
- 125 people
- Sponsor
- Medical University of Vienna